VIVES is a multi-sector fund that invests in projects with a positive societal impact
The Tessares solution combines existing fixed and mobile networks to increase DSL speed with the speed of the 4G mobile network. This is called "Hybrid Internet", which immediately speeds up the speed...
Eligo Bioscience is the world leader in microbiome in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immunoinflammation...
3D-Side assists surgeons by integrating 3D technologies into the operating room. We combine the precision of engineering with medical expertise to individualize the surgical treatment of each patient...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
Issam Doghri, professor at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease